These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 16160010

  • 1. Bmi-1 is useful as a novel molecular marker for predicting progression of myelodysplastic syndrome and patient prognosis.
    Mihara K, Chowdhury M, Nakaju N, Hidani S, Ihara A, Hyodo H, Yasunaga S, Takihara Y, Kimura A.
    Blood; 2006 Jan 01; 107(1):305-8. PubMed ID: 16160010
    [Abstract] [Full Text] [Related]

  • 2. Evaluation of apoptosis as a prognostic factor in myelodysplastic syndromes.
    Shimazaki K, Ohshima K, Suzumiya J, Kawasaki C, Kikuchi M.
    Br J Haematol; 2000 Sep 01; 110(3):584-90. PubMed ID: 10997968
    [Abstract] [Full Text] [Related]

  • 3. The role of apoptosis, proliferation, and the Bcl-2-related proteins in the myelodysplastic syndromes and acute myeloid leukemia secondary to MDS.
    Parker JE, Mufti GJ, Rasool F, Mijovic A, Devereux S, Pagliuca A.
    Blood; 2000 Dec 01; 96(12):3932-8. PubMed ID: 11090080
    [Abstract] [Full Text] [Related]

  • 4. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
    Zhang Z, Xie J.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun 01; 11(3):274-7. PubMed ID: 12844412
    [Abstract] [Full Text] [Related]

  • 5. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis.
    Ohshima K, Karube K, Shimazaki K, Kamma H, Suzumiya J, Hamasaki M, Kikuchi M.
    Leuk Lymphoma; 2003 Aug 01; 44(8):1339-46. PubMed ID: 12952227
    [Abstract] [Full Text] [Related]

  • 6. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S, Mick R, Xu F, Stonys E, Le Beau MM, Larson R, Vardiman JW.
    Leukemia; 1996 Jan 01; 10(1):20-6. PubMed ID: 8558932
    [Abstract] [Full Text] [Related]

  • 7. Proliferative indices, cytogenetics, immunophenotye and other prognostic parameters in myelodysplastic syndromes.
    Varma N, Varma S.
    Indian J Pathol Microbiol; 2008 Jan 01; 51(1):97-101. PubMed ID: 18417875
    [Abstract] [Full Text] [Related]

  • 8. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
    Wei J, Zhou XF, Zhao F, Zhou JF, Chen Y.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb 01; 17(1):111-6. PubMed ID: 19236759
    [Abstract] [Full Text] [Related]

  • 9. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
    Ghaddar HM, Stass SA, Pierce S, Estey EH.
    Leukemia; 1994 Oct 01; 8(10):1649-53. PubMed ID: 7934160
    [Abstract] [Full Text] [Related]

  • 10. Significant correlation between the degree of WT1 expression and the International Prognostic Scoring System Score in patients with myelodysplastic syndromes.
    Cilloni D, Gottardi E, Messa F, Fava M, Scaravaglio P, Bertini M, Girotto M, Marinone C, Ferrero D, Gallamini A, Levis A, Saglio G, Piedmont Study Group on Myleodysplastic Syndromes.
    J Clin Oncol; 2003 May 15; 21(10):1988-95. PubMed ID: 12743153
    [Abstract] [Full Text] [Related]

  • 11. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A, Mattern D, Köhler H, Hezel J, Lübbert M.
    Pathologe; 2000 Jan 15; 21(1):1-15. PubMed ID: 10663664
    [Abstract] [Full Text] [Related]

  • 12. CD34/QBEND10 immunostaining in bone marrow biopsies: an additional parameter for the diagnosis and classification of myelodysplastic syndromes.
    Baur AS, Meugé-Moraw C, Schmidt PM, Parlier V, Jotterand M, Delacrétaz F.
    Eur J Haematol; 2000 Feb 15; 64(2):71-9. PubMed ID: 10997326
    [Abstract] [Full Text] [Related]

  • 13. Fas/Apo-1 (CD95) expression and apoptosis in patients with myelodysplastic syndromes.
    Bouscary D, De Vos J, Guesnu M, Jondeau K, Viguier F, Melle J, Picard F, Dreyfus F, Fontenay-Roupie M.
    Leukemia; 1997 Jun 15; 11(6):839-45. PubMed ID: 9177438
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Immunohistochemical detection of vascular endothelial growth factor (VEGF) in the bone marrow in patients with myelodysplastic syndromes: correlation between VEGF expression and the FAB category.
    Wimazal F, Krauth MT, Vales A, Böhm A, Agis H, Sonneck K, Aichberger KJ, Mayerhofer M, Simonitsch-Klupp I, Müllauer L, Sperr WR, Valent P.
    Leuk Lymphoma; 2006 Mar 15; 47(3):451-60. PubMed ID: 16396768
    [Abstract] [Full Text] [Related]

  • 16. Detection of risk groups in myelodysplastic syndromes. A multicenter study.
    Belli C, Acevedo S, Bengio R, Arrossagaray G, Watman N, Rossi N, García J, Flores G, Goldztein S, Larripa I.
    Haematologica; 2002 Jan 15; 87(1):9-16. PubMed ID: 11801460
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Growth analysis of marrow CD34-positive hematopoietic progenitor cells in patients with myelodysplastic syndromes.
    Asano H, Hotta T, Ichihara M, Murate T, Kobayashi M, Saito H.
    Leukemia; 1994 May 15; 8(5):833-8. PubMed ID: 7514249
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Myelodysplastic syndrome in children: differentiation from acute myeloid leukemia with a low blast count.
    Chan GC, Wang WC, Raimondi SC, Behm FG, Krance RA, Chen G, Freiberg A, Ingram L, Butler D, Head DR.
    Leukemia; 1997 Feb 15; 11(2):206-11. PubMed ID: 9009082
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.